Cleveland Clinic pursues RVAD
This article was originally published in The Gray Sheet
Executive Summary
Clinic's biomedical engineering department will develop a right-ventricle version of Arrow International's CorAide left-ventricular assist device, also created at the Cleveland Clinic. RVAD development will be funded by a $6.95 mil., five-year contract from the National Heart, Lung & Blood Institute. "If the CorAide LVAD can be modified and used as an RVAD, the resulting CorAide biventricular assist device would be an ideal system for patients who need support for their LVAD to function properly," explained project leader Kiyotaka Fukamachi, MD/PhD. The CorAide LVAD currently is in a European pilot study (1"The Gray Sheet" April 19, 2004, p. 23)...
You may also be interested in...
Arrow’s LionHeart To Receive New Power Source; U.S. Trial Awaits EU Testing
A European pilot study of Arrow International's CorAide continuous-flow ventricular assist system is expected to resume by year-end, following ongoing bench testing of modifications, the firm says
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.